Atomo Diagnostics Ltd. (AU:AT1)
ASX:AT1
Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$18.05M
Enterprise ValueAU$15.26M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-to-equity ratio of 0.03 indicates minimal leverage and low interest burden, giving the company durable balance-sheet flexibility. This reduces refinancing risk and supports continued R&D and commercialization spending even while operating results recover, improving resilience.
Proprietary RDT Platform And B2B ModelAtomo’s proprietary rapid diagnostic platform and B2B commercial model (device sales, consumables, customisation, contract manufacturing) creates multiple, recurring revenue channels and sticky partner relationships. Platform licensing and design-for-manufacture services support scalable, long-term revenue if adoption grows.
Relatively High Gross Margin On ProductsA gross margin near 47% implies strong unit economics at the device/consumable level. If volumes recover and fixed costs are leveraged, this margin profile offers a credible path to sustainable operating profitability and cash generation as manufacturing efficiency and scale improve.
Bears Say
Declining Revenue TrendRevenue fell roughly 10% in the latest period, signalling weakening demand or execution shortfalls. Persistent top-line declines undermine operating leverage, make it harder to cover fixed costs, and reduce the runway for commercial investments, heightening medium-term funding and growth risk.
Severe Negative ProfitabilityVery large negative net and EBIT margins indicate structural profitability weaknesses beyond temporary items. Such deep losses erode shareholder equity, limit reinvestment in product and sales, and make recurring external financing likely, constraining strategic options over the medium term.
Negative Operating And Free Cash FlowOperating and free cash flows are negative and FCF declined ~44%, showing worsening cash generation. Continued cash burn forces reliance on external funding, increases dilution risk, and limits the firm's ability to scale commercialization or absorb setbacks without raising capital.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$18.05M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 103 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Currently, no data Available
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AT1 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
-58.40%
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Technical Analysis
Options Prices
Currently, No data available
---